Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases
The Pharma Data
NOVEMBER 15, 2020
R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. “Our ambition is to develop life-changing treatments for patients. Lead Pharma may receive payments of up to €260 million plus royalties on sales. About Lead Pharma.
52 
Let's personalize your content